Search results
Showing 1201 to 1250 of 8236 results
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)
NICE is unable to recommend the use in the NHS of decitabine for acute myeloid leukaemia. This is because Janssen did not provide an evidence submission.
Show all sections
Sections for TA270
NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia. This is because Lilly did not provide an evidence submission
Show all sections
Sections for TA273
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care. his is because TMC Pharma Services did not provide an evidence submission.
Show all sections
Sections for TA277
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
Evidence-based recommendations on olaparib (Lynparza) for BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy in adults.
View recommendations for TA1040Show all sections
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) (TA1028)
NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.
Show all sections
Sections for TA1028
NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission.
Show all sections
Sections for TA1029
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Evidence-based recommendations on vamorolone (Agamree) for treating Duchenne muscular dystrophy in people 4 years and over.
Show all sections
NICE is unable to make a recommendation on melphalan (Phelinun) for treating haematological diseases before allogeneic haematopoietic stem cell transplant because ADIENNE did not provide an evidence submission.
Show all sections
Sections for TA822
Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
Show all sections
Sections for TA1032
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable. This is because Celgene technology did not provide an evidence submission.
Show all sections
Sections for TA362
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)
Evidence-based recommendations on imatinib (Glivec) for treating gastrointestinal stromal tumours in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder. This is because Alexza Pharmaceuticals did not provide an evidence submission.
Show all sections
Sections for TA286